康方生物(09926.HK):根據一般授權配售2480萬股新股 總籌約11.82億港元
格隆匯3月21日丨康方生物(09926.HK)發佈公吿,2024年3月21日,公司與配售代理(即Morgan Stanley Asia Limited及中信里昂證券有限公司)訂立配售協議,據此,公司已有條件同意透過配售代理,以每股配售股份47.65港元的價格,向不少於六名承配人配售合共2480萬股配售股份。
配售股份相當於公司現有已發行股本約2.95%及緊隨配售後經擴大已發行股本約2.86%。配售股份將根據一般授權配發及發行,無需股東批准。假設2480萬股配售股份獲悉數認購,配售完成後,所得款項總額將為11.8172億港元,配售所得款項淨額估計為11.7018億港元。
配售所得款項淨額將用於以下用途:(i)65%將用於以下各項研發:(a)多項進入IND階段的臨牀前項目;(b)開發技術平台(即ADC平台);及(c)加快推進卡度尼利(AK104、PD-1/CTLA-4)、萊法利(AK117、CD47)等的全球臨牀試驗;(ii)25%將用於卡度尼利及依沃西的商業化;及(iii)10%將用於其他一般企業用途(如適用)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.